Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

DIAGNOSTEK's ACQUISITION OF HEALTH CARE SERVICES INC. moves the magnetic resonance imaging firm into the mail order pharmacy business and boosts annual sales to the $100 mil. level. Announced Feb. 29, the purchase involves a $250,000 cash payment, 1.1 mil. shares of Diagnostek stock, and an earn-out on future Health Care Services cash flow. Exclusive of the earn-out, the deal has an initial value of about $1.8 mil., based on Diagnostek stock's Feb. 26 close of 1-7/16. "We are excited to have been able to gain entry into one of the fastest growing areas of health care today through this acquisition," Diagnostek Chairman Nunzio DeSantis remarked. "With the changes implemented by Diagnostek's management over the past 30 days, we feel confident that Health Care Services' margins will be comparable to those of our competitors in the industry." A privately held firm based in Bala Cynwyd, Pennsylvania, Health Care Services generated revenues of $53 mil. for the 12 months ended March 31, 1987. The company fills approximately 10,000 prescriptions per day out of a 96,000 sq. ft. facility, employing 40 pharmacists and 100 technicians. Diagnostek said it plans to build a second prescription filling facility in Albuquerque, N.M., where the company is headquartered. Founded by DeSantis in 1983, Diagnostek establishes magnetic resonance imaging (MRI) centers nationwide through joint ventures with hospitals. Ten have been established so far, with five to six planned for each of the next few years, DeSantis said. Under a typical arrangement, Diagnostek builds and equips an MRI center at a hospital and then provides marketing support. The hospital supplies operating personnel and pays Diagnostek a fee for each patient undergoing an MRI procedure. "Because the hospital rents the MRI center from Diagnostek, paying a predetermined fee for each patient procedure performed with the equipment, the hospital avoids the major capital expenditure or lease commitment of anywhere from $1.8 mil. to $2.2 mil. for the sophisticated equipment," the company explained in a press backgrounder. Although Diagnostek assumes the risk that procedure rental fees are below Diagnostek's equipment costs, Diagnostek is able to significantly minimize its downside from such an arrangement by both pre-qualifying the hospital and obtaining contractural commitments from the hospital to pay a minimum monthly rent after the second year." Diagnostek's fiscal 1987 (year ended March 31) revenues were $3.5 mil. However, combined with the Health Care Services operation, the company's revenues are currently annualizing at $100 mil., according to DeSantis. The U.S. market for mail service pharmaceuticals, DeSantis said, "has grown by 30-50% annually, reaching at least $800 mil. in 1986 and is expected to exceed $2.8 bil. by 1991." Before establishing Diagnostek, DeSantis, a pharmacist, worked for Nuclear Pharmacies, which was recently merged into Syncor. Through similar joint venture arrangements, Syncor establishes centralized nuclear pharmacies in hospitals nationwide.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts